Chronic Lymphocytic Leukemia Clinical Trial
Ublituximab + Ibrutinib in Select B-cell Malignancies
Summary
The purpose of this study is to evaluate the safety and effectiveness of Ublituximab in combination with Ibrutinib in patients with advanced hematologic malignancies.
Eligibility Criteria
Inclusion Criteria:
Confirmed Mantle Cell lymphoma (MCL) open for enrollment. The Chronic Lymphocytic Leukemia (leukemia-cll/" >CLL) enrollment arm is now closed.
Refractory to or relapsed after at least 1 prior treatment regimen
Eastern Cooperative Oncology Group (ECOG) score of 0 to 2
Exclusion Criteria:
Any major surgery, chemotherapy or immunotherapy within the last 21 days
Known hepatitis B virus, hepatitis C virus or HIV infection
Autologous hematologic stem cell transplant within 3 months of study entry. Prior Allogeneic hematologic stem cell transplant is excluded.
Richter's transformation, prolymphocytic leukemia or primary central nervous system lymphoma
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 18 Locations for this study
Huntsville Alabama, 35805, United States
Tucson Arizona, 85710, United States
Santa Barbara California, 93105, United States
Boulder Colorado, 80303, United States
Niles Illinois, 60714, United States
Urbana Illinois, 61801, United States
Bethesda Maryland, 20817, United States
Morristown New Jersey, 07962, United States
Portland Oregon, 97213, United States
Springfield Oregon, 97477, United States
Greenville South Carolina, 29615, United States
Memphis Tennessee, 38120, United States
Austin Texas, 78705, United States
Dallas Texas, 75230, United States
Tyler Texas, 75702, United States
Blacksburg Virginia, 24060, United States
Fairfax Virginia, 22031, United States
Vancouver Washington, 98684, United States
How clear is this clinincal trial information?